Logo

Millennium Takes License to Ingenuity Pathway Analysis Platform

Aug 09, 2004

NEW YORK, Aug. 9 (GenomeWeb News) - Ingenuity Systems said today that Millennium Pharmaceuticals has taken a three-year license to the Ingenuity Pathway Analysis platform, which allows researchers to generate biological networks from gene or protein datasets.

 

Under the companies' arrangement, Ingenuity will also provide Millennium with customized support for research efforts involving the Pathway Analysis technology.

 

Additional terms of the arrangement were not disclosed.

 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.